Thermo Fisher Scientific Inc. (TMO)
- Previous Close
400.48 - Open
393.78 - Bid 394.62 x 1400
- Ask 395.03 x 800
- Day's Range
390.71 - 396.34 - 52 Week Range
390.50 - 627.88 - Volume
1,543,390 - Avg. Volume
2,455,671 - Market Cap (intraday)
148.88B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
23.12 - EPS (TTM)
17.06 - Earnings Date Jul 22, 2025 - Jul 28, 2025
- Forward Dividend & Yield 1.72 (0.43%)
- Ex-Dividend Date Jun 13, 2025
- 1y Target Est
570.17
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
www.thermofisher.com125,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TMO
View More
Performance Overview: TMO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMO
View MoreValuation Measures
Market Cap
151.18B
Enterprise Value
179.42B
Trailing P/E
23.49
Forward P/E
17.86
PEG Ratio (5yr expected)
1.54
Price/Sales (ttm)
3.56
Price/Book (mrq)
3.06
Enterprise Value/Revenue
4.18
Enterprise Value/EBITDA
15.77
Financial Highlights
Profitability and Income Statement
Profit Margin
15.19%
Return on Assets (ttm)
5.00%
Return on Equity (ttm)
13.70%
Revenue (ttm)
42.9B
Net Income Avi to Common (ttm)
6.51B
Diluted EPS (ttm)
17.06
Balance Sheet and Cash Flow
Total Cash (mrq)
5.95B
Total Debt/Equity (mrq)
69.23%
Levered Free Cash Flow (ttm)
5.77B
Research Analysis: TMO
View MoreResearch Reports: TMO
View MoreIt is hard to find anything but good news in the current weekly
It is hard to find anything but good news in the current weekly insider-sentiment data from Vickers Stock Research. Volatility remains the order of the day in the stock market -- but for three consecutive weeks, the data from Vickers has suggested a bottom may be near, or already in. Let's jump right to the numbers. Vickers' NYSE One-Week Sell/Buy Ratio is 1.30 this week, this on a scale where anything below 2.00 is bullish. The ratio has been bullish for the past three weeks. Moving to the Nasdaq, the one-week ratio is 2.40. That is still neutral but closing in on bullish, and the ratio has been strong enough of late to engender nine consecutive weeks of improvement in the broader Nasdaq Eight-Week Sell/Buy Ratio. That reading has improved to 3.28 (neutral) from 5.20 back on March 10. All of the above has Vickers' Total (all exchanges) One-Week Sell/Buy Ratio at a bullish 1.76 and the Total Eight-Week Sell/Buy Ratio close to bullish at 2.63 after nine weeks of improvement. On a sector basis, insider buying exceeded selling in Financials last week, with shares valued at $4.5 million bought versus $3.9 million sold. Buying also outpaced selling in Energy, although volume was light with less than $100,000 shares bought during the period. Selling was the greatest in Consumer Discretionary over the last week, with shares valued at $21 million sold versus just $2 million bought. Selling was also notable in Industrials, Consumer Staples, and Healthcare. This week, analysts at Vickers highlighted insider transactions of interest at HEICO Corp. (NYSE: HEI) and Elevance Health Inc. (NYSE: ELV).
Buying opportunity on pullback in shares
Thermo Fisher manufactures scientific instruments, consumables, and chemicals. It provides analytical instruments, lab equipment, software reagents, and supplies to pharmaceutical companies, hospitals, clinical diagnostic labs, universities, research institutions, and government agencies.
RatingPrice TargetThermo Fisher Earnings: Strong Underlying Performance; Tariffs' Bite Is Manageable
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
RatingPrice TargetLife Science Industry: Tariffs Remain Concerning, but No Major Change to Our Views Currently
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
RatingPrice Target